Although cancer deaths trended higher in the gemfibrozil group (p = 0.11), cancers (excluding basal cell carcinoma) were diagnosed with equal frequency in both study groups. 2002 The rate of gallbladder surgery was not statistically significant between study groups, but did trend higher in the gemfibrozil group, (1.9% vs. 0.3%, p = 0.07). Fenofibric acid exposure is not influenced by age. 2002

(See Concomitant administration of fenofibrate (equivalent to TRICOR 145 mg) with pravastatin (40 mg) once daily for 10 days has been shown to increase the mean CConcomitant administration of a single dose of fenofibrate (equivalent to 145 mg TRICOR) and a single dose of fluvastatin (40 mg) resulted in a small increase (approximately 15-16%) in exposure to (+)3R,5S-fluvastatin, the active enantiomer of fluvastatin. In a single-dose pharmacokinetics study in healthy volunteers, the Triglide 160 mg tablet was shown to have comparable bioavailability to a single dose of 200 mg fenofibrate capsule, micronized. Each tablet contains 48 mg or 145 mg of fenofibrate. cilnidipine. Applies to the following strengths: 48 mg; 145 mg; 54 mg; 160 mg; 67 mg; micronized 200 mg; 134 mg; 40 mg; 120 mg; 43 mg; 130 mg; 30 mg; 90 mg; 50 mg; 150 mgMultiple products available to include micronized capsules, capsules, and tablets: dosing provided for formulations listed below:Multiple products available to include micronized capsules, capsules, and tablets: dosing provided for formulations listed below:Multiple products available to include micronized capsules, capsules, and tablets: dosing provided for formulations listed below:Multiple products available to include micronized capsules, capsules, and tablets: dosing provided for formulations listed below:Dosing is product specific; available as micronized capsules, capsules, and tablets:Dosing is product specific; available as micronized capsules, capsules, and tablets:Dosing is product specific; available as micronized capsules, capsules, and tablets:Elderly: Due to the higher incidence of renal impairment in this patient population, dose selection should be based on renal function; monitor renal function during therapyAlways consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.
Triglide : Strength & form . Increases in liver function tests were the most frequent events, causing discontinuation of fenofibrate treatment in 1.6% of patients in double-blind trials.Additional adverse events reported during post-marketing surveillance or by three or more patients in placebo-controlled trials or reported in other controlled or open trials, regardless of causality are listed below.Accidental injury, allergic reaction, chest pain, cyst, fever, hernia, infection, malaise and pain (unspecified).Angina pectoris, arrhythmia, atrial fibrillation, cardiovascular disorder, coronary artery disorder, electrocardiogram abnormal, extrasystoles, hypertension, hypotension, migraine, myocardial infarct, palpitation, peripheral vascular disorder, phlebitis, tachycardia, varicose vein, vascular disorder, vasodilatation, venous thromboembolic events (deep vein thrombosis, pulmonary embolus) and ventricular extrasystoles. Fenofibrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.In female rats given oral dietary doses of 15, 75, and 300 mg/kg/day of fenofibrate from 15 days prior to mating through weaning, maternal toxicity was observed at 0.3 times the MRHD, based on body surface area comparisons; mg/mIn pregnant rats given oral dietary doses of 14, 127, and 361 mg/kg/day from gestation day 6-15 during the period of organogenesis, adverse developmental findings were not observed at 14 mg/kg/day (less than 1 times the MRHD, based on body surface area comparisons; mg/mIn pregnant rabbits given oral gavage doses of 15, 150, and 300 mg/kg/day from gestation day 6-18 during the period of organogenesis and allowed to deliver, aborted litters were observed at 150 mg/kg/day (10 times the MRHD, based on body surface area comparisons: mg/mIn pregnant rats given oral dietary doses of 15, 75, and 300 mg/kg/day from gestation day 15 through lactation day 21 (weaning), maternal toxicity was observed at less than 1 times the MRHD, based on body surface area comparisons; mg/mIt is not known whether fenofibrate is excreted into milk. Fenofibrate demonstrated a non-significant 11% relative reduction in the primary outcome of coronary heart disease events (hazard ratio [HR] 0.89, 95% CI 0.75-1.05, p=0.16) and a significant 11% reduction in the secondary outcome of total cardiovascular disease events (HR 0.89 [0.80-0.99], p=0.04). 2001 However, Triglide 160 mg tablet exhibits a 32% higher rate of absorption compared to the 200 mg micronized fenofibrate capsule under low-fat fed conditions.

[See USP Controlled Room Temperature]. TRICOR (fenofibrate tablets), is a lipid regulating agent available as tablets for oral administration. The maximum dose is 145 mg once daily.
The benefits and risks of using TRICOR (fenofibrate tablets) with immunosuppressants and other potentially nephrotoxic agents should be carefully considered, and the lowest effective dose employed.Two dietary carcinogenicity studies have been conducted in rats with fenofibrate. 300 mg loading dose followed by 75 mg for 14 days up to 12 months (if no bleeding) Concomitant therapy with aspirin: Administer in combination with aspirin 75-325 mg qDay with or without thrombolytics >75 years. If cholelithiasis is suspected, gallbladder studies are indicated. TRICOR therapy also lowered triglycerides and raised HDL-C (see Table 1).In a subset of the subjects, measurements of apo B were conducted. and formulary information changes.